Immutep (ASX:IMM) has announced positive clinical results from Cohort B of the TACTI-003 (KEYNOTEC34) Phase 2b trial. …
Immutep reports promising new data in head and neck cancer at ESMO immuno-oncology 2024
December 12, 2024 Australian Biotech
Latest Video
New Stories
-
Immutep reports promising new data in head and neck cancer at ESMO immuno-oncology 2024
December 12, 2024 - - Australian Biotech -
What could the HTA Review change for patients who waited for this cancer therapy?
December 12, 2024 - - Latest News -
Health groups call for dying patients to receive free pain relief amid medicines shortage
December 12, 2024 - - Latest News -
QIMR Berghofer says cell therapy saving lives of immunocompromised patients
December 11, 2024 - - Australian Biotech -
Leafio opens Sydney distribution facility to deliver same-day medical cannabis to metro pharmacies
December 11, 2024 - - Latest News -
AusBiotech and BioMelbourne Network welcome Victoria's economic growth statement
December 11, 2024 - - Australian Biotech -
DHL constructing largest automated life sciences warehouse footprint in the Southern Hemisphere
December 11, 2024 - - Latest News